Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant
Clinical Transplantation · 2023
DOI: 10.1111/ctr.15082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Mohammed Alzahrani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Veloxis Pharmaceuticals.
Abstract (Originalsprache)
Introduction
Tacrolimus is known to exhibit significant inter‐ and intra‐patient pharmacokinetic (PK) and pharmacodynamic (PD) variability regarding therapeutic response. LCP‐tacrolimus (LCPT—Envarsus XR) was approved in 2018 for use as a de novo immunosuppressive agent in kidney transplants, but there is limited evidence to guide de novo dosing of LCPT in patients with obesity. The primary objective of this study was to evaluate the impact of different calculated weight‐based de novo LCPT dosing on early transplant outcomes.
Methods
This was a retrospective study of patients with obesity (BMI ≥ 30 kg/m 2 ) who received a kidney transplant at the University of Illinois Hospital and Health System (UIH), between March 2019 and March 2021. Subjects were included if were age 18 years or older and received de novo LCPT throughout index hospitalization. The primary endpoint of this study was to compare correlations between the first tacrolimus trough level and dosing weight strategy (e.g., TBW, AdjBW, IBW).
Results
There was a statistically significant, though modest, correlation between all three dosing strategies and the first tacrolimus trough level (TBW correlation coefficient = .431, p < .001; AdjBW correlation coefficient = .455, p < .001; IBW correlation coefficient = .465; p < .001). In regression modeling for supratherapeutic levels each additional .01 mg/kg increase in dose by TBW, AdjBW, and IBW increased the odds of a supratherapeutic level by 1.46, 1.34, and 1.24, respectively ( p < .001).
Conclusions
The use of LCPT in kidney transplant recipients with obesity dosed using TBW demonstrated the strongest correlation with initial supratherapeutic tacrolimus levels. Larger prospective studies are needed to investigate the further impact of body weight on dosing regimens in the obese population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA.
- Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
ORCID-Profile: Rachel M Belcher, Jamie Benken, Scott T Benken
Förderung
- Veloxis Pharmaceuticals
Zitieren
APA
Alzahrani, M., Belcher, R. M., Benken, J., Valdepenas, B., Di Cocco, P., Kajavathanan, M., & Benken, S. T. (2023). Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant. Clinical Transplantation. https://doi.org/10.1111/ctr.15082
Vancouver
Alzahrani M, Belcher RM, Benken J, Valdepenas B, Di Cocco P, Kajavathanan M, et al. Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant. Clinical Transplantation. 2023. doi:10.1111/ctr.15082
BibTeX
@article{Alzahrani2023,
author = {Alzahrani, Mohammed and Belcher, Rachel M and Benken, Jamie and Valdepenas, Benito and Di Cocco, Pierpaolo and Kajavathanan, Mathula and Benken, Scott T},
title = {Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.15082}
}
EUVIMED